Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis

Campanati, Anna; Paolinelli, Matteo; Diotallevi, Federico; Martina, Emanuela; Molinelli, Elisa; Offidani, Annamaria

doi:10.1080/17425255.2019.1681969

Cited by 25 publications

(24 citation statements)

References 196 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently five TNFα inhibitors are proved for the treatment of psoriasis: infliximab, adalimumab, golimumab, etanercept, and certolizumab pegol. Each presents different posology, indications, and pharmacological profile 27 …”

Section: Biologic Treatmentmentioning

confidence: 99%

Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review

Camela

Ocampo‐Garza

Cinelli

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

Scalp psoriasis represents the most common difficult-to-treat area in psoriasis patients. Its presence is linked to severe discomfort and impairment of quality of life given the associated symptoms (most of all, scaling and pruritus) and the location in a highly visible area, thus a prompt treatment is required. Its management may be challenging as the scalp is quite sensitive to long-term treatment with topical corticosteroids and usually resistant to topical and systemic agents. Likely, the currently available therapeutic armamentarium has been enriched with biologicals and small molecules that revolutionized psoriasis treatment and that of scalp psoriasis. Nevertheless, the lack of international dedicated guidelines pushed us to perform a comprehensive review on the efficacy and safety of biologics and small molecules on scalp psoriasis with the aim to put the basis for a therapeutic algorithm. After reviewing all the available evidence on the short-term and long-term efficacy of biologics and small molecules on scalp psoriasis the use of the newest biologics (anti-IL-17 and anti-IL-23) seems to be linked to the highest clinical performances in controlling scalp psoriasis. However, head-to-head comparisons between different biologics or biologics and small molecules are lacking. Hence, treatment selection should always be individualized.

show abstract

Section: Biologic Treatmentmentioning

confidence: 99%

Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review

Camela

Ocampo‐Garza

Cinelli

et al. 2021

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…In response to TNF, vascular endothelial cells undergo several changes to increase leukocyte adhesion, transendothelial migration, vascular permeability and encourage thrombosis [4] . Excessive production of TNF along with other pro-inflammatory cytokines such as Interleukin-1 (IL-1), Interleukin-6 (IL-6) contributes to the pathological processes associated with rheumatoid arthritis [5] , inflammatory bowel disease [6] , psoriasis [7] and sepsis. Since the approval of infliximab [8] , the first monoclonal antibody against TNF for rheumatoid arthritis (RA), TNF inhibitors including adalimumab, certolizumab, golimumab and the fusion protein etanercept are increasingly utilised as therapy for rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and other inflammatory conditions ( Table 1 ).…”

Section: Introductionmentioning

confidence: 99%

Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19

Patel¹,

Wadhwa²

2021

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has caused significant devastation globally. Despite the development of several vaccines, with uncertainty around global uptake and vaccine efficacy, the need for effective therapeutic agents remains. Increased levels of cytokines including tumour necrosis factor are significant in the pathogenesis of COVID-19 and associated with poor outcomes including ventilator requirement and mortality. Repurposing tumour necrosis factor blocker therapy used in conditions such as rheumatoid arthritis and inflammatory bowel disease seems promising, with early feasibility data showing a reduction in circulation of pro-inflammatory cytokines and encouraging the evaluation of such interventions in preventing disease progression and clinical deterioration in patients with COVID-19. Here, we examine the biological activities of tumour necrosis factor inhibitors indicative of their potential in COVID-19 and briefly outline the randomised control trials assessing their benefit-risk profile in COVID-19 therapy.

show abstract

“…Although we have used a mouse model to study psoriasis-like disease, it is clinically reported that patients with active psoriasis have elevated levels of TNF-α in blood serum and skin lesions [34]. Currently, TNF inhibitors are used for psoriasis therapy [66]; however, due to substantially high cost and risk associated with TNF-α inhibitors [66,67], these are not commonly used. However, WSSO displays natural anti-inflammatory and anti-psoriatic properties by acute and robust inhibition of TNF-α expression.…”

Section: Discussionmentioning

confidence: 99%

Super Critical Fluid Extracted Fatty Acids from Withania somnifera Seeds Repair Psoriasis-Like Skin Lesions and Attenuate Pro-Inflammatory Cytokines (TNF-α and IL-6) Release

et al. 2020

View full text Add to dashboard Cite

(1) Background: Withania somnifera Dunal (Ashwagandha) is a widely used medicinal herb in traditional medicinal systems with extensive research on various plant parts. Surprisingly, seeds of W. somnifera have never been investigated for their therapeutic potential. (2) Methods: W. somnifera seeds were extracted for fatty acids (WSSO) using super critical fluid extraction, and was analyzed by gas chromatography. Its therapeutic potential in psoriasis-like skin etiologies was investigated using a 12-O tetradecanoyl phorbol 13-acetate (TPA)-induced psoriatic mouse model. Psoriatic inflammation along with psoriatic lesions and histopathological scores were recorded. WSSO was also tested on murine macrophage (RAW264.7), human epidermoid (A431), and monocytic (THP-1) cells, stimulated with TPA or lipo poly-saccharide (LPS) to induce pro-inflammatory cytokine (IL-6 and TNF-α) release. NFκB promoter activity was also measured by luciferase reporter assay. (3) Results: Topical application of WSSO with concurrent oral doses significantly reduced inflammation-induced edema, and repaired psoriatic lesions and associated histopathological scores. Inhibition of pro-inflammatory cytokines release was observed in WSSO-treated A431 and THP-1 cells, along with reduced NFκB expression. WSSO also inhibited reactive nitrogen species (RNS) in LPS-stimulated RAW264.7 cells. (4) Conclusion: Here we show that the fatty acids from W. somnifera seeds have strong anti-inflammatory properties, along with remarkable therapeutic potential on psoriasis-like skin etiologies.

show abstract

Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis

Cited by 25 publications

References 196 publications

Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review

Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review

Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19

Super Critical Fluid Extracted Fatty Acids from Withania somnifera Seeds Repair Psoriasis-Like Skin Lesions and Attenuate Pro-Inflammatory Cytokines (TNF-α and IL-6) Release

Contact Info

Product

Resources

About